文献速递白血病

DEK::NUP214白血病的XPO1依赖性

XPO1-dependency of DEK::NUP214 leukemia.
PubMed 文献 · Leukemia · 2025-03-27

该研究在人源AML模型中评估DEK::NUP214(DN)白血病对XPO1的依赖性:敲除XPO1或使用第二代选择性核输出抑制剂eltanexor可降低XPO1表达、破坏XPO1与DN在染色质的共定位、诱导凋亡与细胞周期阻滞。患者来源DN-AML异种移植模型中,eltanexor组骨髓分子清除中位377天,对照组中位244天死亡。

要点

  • 在DN阳性FKH-1细胞中敲除XPO1显示对XPO1的强依赖性。
  • Eltanexor降低XPO1表达、破坏XPO1与DN染色质共定位,诱导凋亡和细胞周期阻滞。
  • 患者来源DN-AML异种移植模型中eltanexor组骨髓分子清除中位377天,对照组中位244天死亡。

核心结论

  • XPO1通过稳定DN在染色质上促进其致癌基因签名激活,靶向XPO1在体内成功治疗白血病。
  • 研究结果将XPO1确立为DEK::NUP214 AML的分子靶点。

研究设计与样本

  • 在人源AML模型中评估DEK::NUP214(DN)白血病对XPO1的依赖性。
  • 在DN阳性FKH-1细胞中进行XPO1敲除。
  • 在原代人细胞和FKH-1细胞中使用eltanexor进行XPO1药理学抑制。
  • 使用患者来源DN-AML异种移植模型评估eltanexor体内效果。

主要发现

  • DN阳性FKH-1细胞中敲除XPO1显示对XPO1的强依赖性。
  • Eltanexor在原代人细胞和FKH-1细胞中降低XPO1表达、破坏XPO1与DN共定位、诱导凋亡和细胞周期阻滞。
  • XPO1与DN在染色质共定位,XPO1抑制后该共定位强烈减少,染色质结合丧失导致DN靶基因及细胞周期和自我更新相关通路下调。
  • 患者来源DN-AML异种移植模型中,eltanexor组骨髓分子清除中位377天,对照组中位244天死亡。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The nuclear export protein XPO1 interacts with nucleoporin 214 (NUP214) and has been implicated in the pathogenesis of SET::NUP214 acute myeloid leukemia (AML). We evaluated DEK::NUP214 (DN), characterizing a distinct AML entity, for its dependency on XPO1 in human AML models. Deletion of XPO1 in DN-positive FKH-1 cells revealed a strong dependency on XPO1. Pharmacologic inhibition of XPO1 by the second-generation selective inhibitor of nuclear export, eltanexor, in primary human and FKH-1 cells reduced XPO1 expression, disrupted co-localization of XPO1 and DN, and induced apoptosis and cell cycle arrest. Functionally, XPO1 and DN co-localized at chromatin, and this co-localization was strongly reduced by XPO1 inhibition. Loss of chromatin binding resulted in downregulation of DN target genes and pathways related to cell cycle and self-renewal. Eltanexor treatment of a patient-derived DN-AML xenograft model disrupted leukemia development, showing molecular clearance in bone marrow after a median of 377 days in eltanexor-treated mice, while control mice succumbed after a median of 244 days. In summary, XPO1 stabilizes DN at chromatin to allow the activation of its oncogenic gene signature, while targeting XPO1 treats leukemia successfully in vivo. These findings establish XPO1 as a molecular target in DEK::NUP214 AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Charles Cano F, Kloos A, Hebalkar RY, et al. XPO1-dependency of DEK::NUP214 leukemia. Leukemia. 2025. PMID: 40148556. doi:10.1038/s41375-025-02570-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。